Sun Qing, Wang Na, Xu Wenhua, Zhou Huakun
Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, Qinghai, 810008, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, Qinghai, 810008, China.
J Ethnopharmacol. 2021 Aug 10;276:114166. doi: 10.1016/j.jep.2021.114166. Epub 2021 Apr 30.
The genus Ribes Linn., which belongs to the Grossulariaceae family, contains 160 species distributed mainly in temperate and cold regions of the Northern Hemisphere. There are 59 species in southwest, northwest and northeast China. Some species of Ribes have been used as traditional and local medicines for the treatment of glaucoma, cardiovascular disease, stomachache, hepatitis, hyperlipidemia, hypertension and other ailments. However, the data provided in recent years have not been collated and compared.
This review aims to summarize the current status of ethnopharmacological uses, phytochemistry, pharmacology, clinical applications, and pharmacokinetics of the genus Ribes to better understand the therapeutic potential of the genus Ribes in the future and hope to provide a relatively novel perspective for further clinical application on the genus.
The literature on Ribes was collected through a series of scientific search engines including Elsevier, ACS, Springer, Web of Science, PubMed, Google Scholar, Baidu Scholar, Wiley, China National Knowledge Infrastructure (CNKI) and books.
Ribes species have been used for detoxification, glaucoma, cardiovascular disease, stomachache, hepatitis, hyperlipidemia, hypertension and other ailments. These plants mainly contain phenolic glycosides, flavonoids, proanthocyanidins, polysaccharides, etc. Most traditional uses are related to biological activity and have been confirmed by modern research. Pharmacological studies in vitro and in vivo revealed that the extracts and pure compounds possessed significant hypolipidemic, antioxidant, anti-inflammatory, antitumor, antibacterial, and antiviral activity, eyesight protection and other effects.
The traditional uses, phytochemistry, pharmacology, pharmacokinetics, and clinical applications described in this article explained that the Ribes species has numerous activities, and these findings will promote further action in the area of mechanism research. However, very few preclinical and clinical studies have focused on the toxicology and pharmacokinetics of crude extracts and pure compounds from the genus Ribes. Moreover, several clinical evidence to support the health benefits of Ribes plants. The development of new medicines based on Ribes species as ingredients may be restricted. The pharmacological activity, clinical efficacy and safety of Ribes species need to be verified by systematic and comprehensive preclinical studies and clinical trials.
茶藨子属（Ribes Linn.）隶属于虎耳草科，包含160个物种，主要分布于北半球的温带和寒带地区。中国西南、西北和东北地区有59个物种。茶藨子属的一些物种已被用作传统的地方药物，用于治疗青光眼、心血管疾病、胃痛、肝炎、高脂血症、高血压和其他疾病。然而，近年来所提供的数据尚未进行整理和比较。
本综述旨在总结茶藨子属在民族药理学用途、植物化学、药理学、临床应用和药代动力学方面的现状，以便更好地了解茶藨子属未来的治疗潜力，并希望为该属的进一步临床应用提供一个相对新颖的视角。
通过一系列科学搜索引擎收集有关茶藨子属的文献，包括爱思唯尔（Elsevier）、美国化学学会（ACS）、施普林格（Springer）、科学网（Web of Science）、PubMed、谷歌学术（Google Scholar）、百度学术、威利（Wiley）、中国知网（CNKI）及书籍。
茶藨子属物种已被用于解毒、治疗青光眼、心血管疾病、胃痛、肝炎、高脂血症、高血压和其他疾病。这些植物主要含有酚苷、黄酮类化合物、原花青素、多糖等。大多数传统用途与生物活性相关，并已得到现代研究的证实。体外和体内药理学研究表明，提取物和纯化合物具有显著的降血脂、抗氧化、抗炎、抗肿瘤、抗菌和抗病毒活性、保护视力等作用。
本文所述的传统用途、植物化学、药理学、药代动力学和临床应用表明茶藨子属物种具有多种活性，这些发现将促进该领域在作用机制研究方面的进一步行动。然而，极少有临床前和临床研究关注茶藨子属粗提物和纯化合物的毒理学和药代动力学。此外，支持茶藨子属植物对健康有益的临床证据较少。以茶藨子属物种为成分的新药开发可能会受到限制。茶藨子属物种的药理活性、临床疗效和安全性需要通过系统全面的临床前研究和临床试验来验证。
